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Abstract
HIV Prevention Trials Network (HPTN) 052 demonstrated that antiretroviral therapy (ART) 
prevents HIV transmission in serodiscordant couples. HIV from index-partner pairs was analyzed 
to determine the genetic linkage status of partner infections. Forty-six infections were classified as 
linked, indicating that the index was the likely source of the partner’s infection. Lack of viral 
suppression and higher index viral load were associated with linked infection. Eight linked 
infections were diagnosed after the index started ART: four near the time of ART initiation and 
four after ART failure. Linked infections were not observed when the index participant was stably 
suppressed on ART.
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INTRODUCTION
The HIV Prevention Trials Network (HPTN) 052 trial was a Phase 3, randomized, controlled 
trial that tested whether early initiation of antiretroviral therapy (ART) prevented sexual 
transmission of HIV in serodiscordant couples.1,2 Index participants in the early ART arm 
started ART at study enrollment with baseline CD4 cell counts of 350–550 cells/mm3. Index 
participants in the delayed ART arm started ART when their CD4 count fell below 250 
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cells/mm3 or they developed an AIDS-defining illness. The primary endpoints for the trial 
were genetically-linked partner infections (i.e., infections where the enrolled index 
participant was the likely source of the partner’s infection). In April 2011, an interim 
analysis demonstrated that early ART prevented 96% of linked HIV infections and offered 
health benefits to the individual receiving ART.1,3 After these results were released, ART 
was offered to all HIV-infected index participants regardless of CD4 cell count. The trial 
continued until May 2015, to assess the durability of the study intervention. The final intent-
to-treat analysis found that early ART prevented 93% of linked HIV infections.2 In this 
report, we present genetic linkage analysis and characterization of partner infections in 
HPTN 052, and analysis of the association of demographic, behavioral, and clinical factors 
with linked HIV infection.
METHODS
Study cohort
HPTN 052 enrolled 1,763 serodiscordant couples at 13 study sites in Africa, Asia, and the 
Americas (97% heterosexual, April 2005-May 2010).1 ART failure was defined as the first 
of two consecutive study visits where the index’s viral load was >1,000 copies/mL more 
than 24 weeks after ART initiation. HIV-uninfected partners were tested for HIV infection 
throughout the trial, as described;1 partner infections were confirmed at the HPTN 
Laboratory Center (Baltimore, MD, USA).
Linkage analysis
Genetic linkage of partner infections was determined using phylogenetic and statistical 
methods described previously.4 Linkage analysis was performed using samples collected 
from partners with confirmed HIV infection and the corresponding index participants 
(index-partner pairs); whenever possible, two samples from each individual were analyzed. 
Samples from random index participants at the same study sites were also analyzed (control 
samples). Three methods were used for linkage analysis: phylogenetic analysis of HIV pol 
sequences generated from population-sequencing; Bayesian analysis of pol sequence data; 
and phylogenetic analysis of env sequences obtained by next generation sequencing 
(Supplemental Digital Content 1).
HIV drug resistance testing and HIV subtyping
HIV genotyping was performed using the ViroSeq HIV-1 Genotyping System (Celera 
Diagnostics, Alameda, CA). HIV subtyping was performed using the resulting pol region 
sequences, as described.4
Analysis of factors associated with linked vs. unlinked partner infections
Associations between linkage status and categorical variables were assessed using Fisher’s 
exact test. Associations between linkage status and continuous variables were assessed using 
Wilcoxon’s rank sum test. All p-values are two-sided. Statistical significance was defined as 
p<0.05. Backwards stepwise multivariate logistic regression was performed using a cutoff of 
<0.05 to retain the factors considered significant.
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Analysis of the timing of partner infections
The timing of partner infections was analyzed in three cases as described5 using HIV RNA 
testing; serologic assays; and sequence analysis using BEAST (which estimates the time 
since HIV infection using phylogenetic methods for analysis of sequence data6) and Poisson 
Fitter (which estimates the time since HIV infection based on the accumulation of neutral 
mutations in the viral population7).
Informed consent
Ethical review committees at each participating institution approved the HPTN 052 trial 
(NCT00074581). Written informed consent was obtained from all study participants.
RESULTS
Linkage status of index-partner pairs
Seventy-eight partner infections were observed over 8,295 person-years of follow-up for 
uninfected partners, including 6,620 person-years of follow-up for partners after the 
corresponding index participant started ART. Forty-six infections were diagnosed before the 
index participant started study ART, and 32 were diagnosed after the index participant 
started study ART (19 in the early ART arm and 13 in the delayed ART arm, Figure 1A).
Linkage of partner infections was assessed using phylogenetic and statistical methods 
(Supplemental Digital Content 1). HIV sequencing and linkage analysis were successful for 
72 of the 78 cases; in the other six cases, samples were not available for analysis or 
amplification failed for either the index or partner samples. Overall, 46 infections were 
classified as linked and 26 were classified as unlinked (Figure 1A). Figure 1B shows the 
timing of linked and unlinked infections in each study arm, relative to key study milestones.
In all cases, HIV subtypes were consistent with the subtypes prevalent in the region 
(Supplemental Digital Content 2A). HIV drug resistance was detected in HIV from the 
partner in only two of the 46 linked cases; in both cases, the same resistance mutations were 
detected in the corresponding index participant, suggesting that the resistant virus was 
transmitted (Supplemental Digital Content 2B). Both of these cases occurred in the delayed 
ART arm, before the index participant started ART. HIV drug resistance was detected in the 
partner in only two of the 26 unlinked cases; in these cases, resistance mutations were not 
detected in HIV from the index participant (Supplemental Digital Content 2B).
Factors associated with linked infections
We analyzed the association of clinical, demographic, and behavioral factors with linked 
partner infections (Supplemental Digital Content 3). In univariate analyses, linked partner 
infections were associated with the following characteristics: couple randomized to the 
delayed ART arm; index participant not on ART at the time of partner diagnosis; higher 
index viral load at the time of partner diagnosis (index viral load >400 copies/mL or higher 
log10 viral load); lower index CD4 cell count at the time of partner diagnosis; shorter time 
between enrollment and partner diagnosis; and fewer sexual partners in the three months 
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prior to diagnosis. Region (Africa vs. Asia/Americas) and index sex were not associated 
with linked infection.
Backwards stepwise regression models were used for model building in multivariate 
analysis; separate analyses were used for each measure of index viral load at the time of 
partner infection (greater or less than 400 copies/mL or log10 viral load). In both models, 
higher index viral load was strongly associated with linked infection (p=0.0006 and 
p<0.0001). When index viral load was analyzed as a binary variable (greater or less than 400 
copies/mL), randomization in the delayed ART arm and lower index CD4 cell count at the 
time of partner diagnosis were also associated with linked partner infection (p=0.045 and 
p=0.033, respectively). When index viral load was analyzed as a continuous variable 
(median log10 viral load), the only factor significantly associated with linked infection was 
index viral load at the time of partner diagnosis.
Linked partner infections diagnosed after the index participant started ART
Eight of the 46 linked infections occurred after the index participant started ART (three in 
the early ART arm; five in the delayed ART arm, Figure 1B, key cases); these eight cases 
were analyzed in detail. None of the eight partners in these key cases had HIV drug 
resistance. In four cases, the partner was diagnosed after the index participant failed ART 
(Supplemental Digital Content 4, Panel A). In three of these four cases, the index was 
viremic at the time of partner diagnosis. In the fourth case, the index was intermittently 
viremic prior to the partner diagnosis; in that case, the partner was lost-to-follow up for more 
than one year; during that time, the partner was diagnosed with HIV infection and had 
started ART. In the other four cases, the partner was diagnosed with HIV infection shortly 
after the index participant started ART (Supplemental Digital Content 4, Panel B). In one of 
those four cases, the index participant did not achieve virologic suppression on ART and was 
viremic when the partner was diagnosed with HIV infection. In the other three cases (Cases 
A–C), the index’s viral load was <400 copies/mL when the partner was diagnosed with HIV 
infection.
Additional laboratory assessments were performed in Cases A–C to estimate the timing of 
HIV transmission relative to index ART initiation (Figure 2). Results obtained for two of 
these cases are described in a previous report5 and are updated here. In all three cases, the 
analyses indicated that the transmission event occurred either before index ART initiation 
(when the index was not virally suppressed), or shortly after index ART initiation (most 
likely before the index was virally suppressed from ART). Of note, in HPTN 052, the 
cumulative percentage of index participants who achieved viral suppression by 3, 6, 9, and 
12 months were 76%, 87%, 90%, and 91%.
DISCUSSION
Phylogenetic methods can be used to study HIV transmission networks and hotspots within 
communities and populations8–10 and to assess the genetic linkage of specific transmission 
events.4,11 In this study, we used phylogenetic and statistical methods to identify genetically-
linked partner infections in the HPTN 052 trial, which were the basis of the primary 
endpoint analysis for this landmark study.1,2 This report highlights the importance of genetic 
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linkage analysis in evaluating HIV transmission in clinical trials that include serodiscordant 
couples. Forty-six linked partner infections were observed in the HPTN 052 trial. Only eight 
of these infections were diagnosed after the index participant started ART. We identified 
three risk periods for index-to-partner (linked) transmission in couples after the index 
participant had started ART: (1) near the time of ART initiation, before viral suppression 
was achieved, (2) after ART initiation if viral suppression did not occur, and (3) after ART 
failure.
High HIV viral load is a major driver of sexual HIV transmission and is also associated with 
ART outcomes that are relevant to use of treatment as prevention. In a previous study, we 
showed that higher baseline viral load in index participants was associated with a longer 
time to viral suppression and lack of viral suppression 3 or 6 months after ART initiation 
was associated with a shorter time to ART failure and a higher frequency of ART failure.12 
In this report, higher index viral load at study enrollment2 and higher index viral load at the 
time of partner seroconversion were associated with linked partner infection.
In most cases, several months of ART is required before viral suppression is achieved. More 
rapid viral suppression is observed with ART regimens that include integrase inhibitors;13,14 
however, these regimens may not be available in resource-limited settings. Previous studies 
have examined the risk of HIV transmission in the months after ART initiation. In a review 
of six studies of serodiscordant couples, only one linked infection was observed >6 months 
after ART initiation among 1,672 couples with 2,773 person-years of follow-up.15 In another 
study, no infections were observed >6 months after ART initiation (over 167 person-years 
follow-up).16 In HPTN 052, four linked infections were observed >6 months after ART 
initiation (over 7,032 person-years of follow-up); all four cases occurred long after ART 
failure. Importantly, we did not observe any linked infections in couples where the index 
participant was stably suppressed on ART. These data were based on 6,620 person-years of 
follow-up of partners after index ART initiation.
This report highlights the importance of achieving and maintaining viral suppression when 
ART is used to reduce the risk of HIV transmission. In this setting, special efforts should be 
made to minimize HIV transmission risk before the index is virally suppressed, to achieve 
durable viral suppression on ART, and to identify and address ART failure early.
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Figure 1. Analysis of partner infections in HPTN 052
(A) The chart shows an overview of the linkage status of partner infections in HPTN 052. 
Data are presented separately for couples where the partner was diagnosed with HIV 
infection before the index participant started antiretroviral therapy (ART) in the trial (N=46) 
or after the index participant started ART in the trial (N=32). Infections were classified as 
linked if the index participant was the likely source of the partner’s infection, and unlinked if 
the partner was most likely infected from another source.
(B) Seventy-eight partner infections were identified in the HPTN 052 trial. The dates 
(month/year) of milestones in the HPTN 052 trial are shown on the X-axis. A vertical 
dashed line indicates the date that the interim report was released, showing the benefit of 
early initiation of ART. Horizontal arrows show the number of person-years of follow-up for 
partners who were HIV-uninfected at study enrollment. Partner infections are represented by 
diamonds. Data are presented separately for linked and unlinked partner infections. Open 
diamonds indicate infections in the delayed ART arm of the study that were diagnosed 
before the index participant started ART. Shaded diamonds indicate infections in the delayed 
ART arm of the study that were diagnosed after the index participant started ART. Black 
diamonds indicate infections in the Early ART arm of the study, all of which were diagnosed 
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after the index participant started ART. Eight linked partner infections were diagnosed after 
the index started ART (Key cases, arrows).
aIn six cases, linkage status could not be determined because HIV RNA in the index and/or 
partner sample(s) could not be amplified (failed cases). In three cases, HIV RNA could not 
be amplified because the index was virally suppressed at all study visits (including the 
enrollment visit). In two of those cases, the index participant was on ART at study 
enrollment, but did not disclose this to study staff17; in the third case, ARV drugs were not 
detected in study specimens, indicating that the index participant was most likely an elite 
controller. In the fourth case, the partner was diagnosed with HIV infection and started ART 
outside of the study and was virally suppressed at subsequent study visits. It is not clear why 
amplification was unsuccessful in the other two cases. In those cases, attempts to amplify 
HIV RNA using a nested PCR method and alternate amplification primers were not 
successful.
b3 early ART arm; 5 delayed ART arm.
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Figure 2. Analysis of the timing of linked partner infections that were diagnosed when the index 
participant was virally suppressed
The figure shows data for three partner infections where the partner was diagnosed shortly 
after the index participant started antiretroviral therapy (ART), when the index was virally 
suppressed. The vertical line at Day 0 indicates the day of that the index participant started 
ART. Days before the start of ART are indicated with negative numbers; days after the start 
of ART are shown with positive numbers. Index and partner viral load (VL) values are 
indicated. The date of the partner’s first positive HIV test is indicated (WB+: Western blot 
positive). The solid horizontal lines indicate the estimated transmission date with 95% 
confidence intervals (CI) obtained using BEAST. Dotted lines indicate the estimated 
transmission date with 95% CI obtained using the Poisson Fitter. Dashed lines indicate the 
time between the earliest possible transmission date (7 days before the partner’s last test 
where HIV RNA was undetectable) and the end of the likely transmission period, 
determined by the Fiebig stage18 of the partner at the first HIV positive visit. (A) In Case A, 
Eshleman et al. Page 13
J Acquir Immune Defic Syndr. Author manuscript; available in PMC 2018 January 01.
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
the partner was diagnosed with HIV infection on Day +35. HIV RNA was undetectable (<40 
copies/mL) on Day −35, indicating that the earliest possible transmission date was Day −42 
(based on a 7-day eclipse period). The Western blot was positive on Day +35 (Fiebig stage 
V18), indicating that the transmission event occurred before Day +12. BEAST analysis 
estimated that the transmission event occurred on Day −5. Poisson fitter analysis estimated 
that the transmission event occurred on Day +1. (B) In Case B, the partner was diagnosed 
with HIV infection on Day +84. HIV RNA was undetectable on Day −1, indicating that the 
earliest possible transmission date was Day −8. The Western blot was positive on Day +84 
(Fiebig stage VI18), indicating that the transmission event occurred before Day +29. BEAST 
analysis estimated that the transmission event occurred on Day 0. Poisson fitter analysis was 
not performed in this case because of the complexity of the partner’s viral population5. (C) 
In Case C, the partner was diagnosed with HIV infection on Day +59. HIV RNA was 
undetectable on Day 0, indicating that the earliest possible transmission date was Day −7. 
The Western blot was positive on Day +59 (Fiebig stage V18), indicating that the 
transmission event occurred before Day +36. BEAST analysis estimated that the 
transmission event occurred on Day +5. Poisson fitter analysis estimated that the 
transmission event occurred on Day +17.
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